Supernus Pharmaceuticals

ISIN US8684591089

 | 

WKN A1JX3U

Market cap (in EUR)
2,268 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 2,268 m
EPS, EUR -0.31
P/B ratio 2.5
P/E ratio 48.7
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 612 m
Net income, EUR 68 m
Profit margin 11.16%

What ETF is Supernus Pharmaceuticals in?

There are 5 ETFs which contain Supernus Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Supernus Pharmaceuticals is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.28%
Equity
United States
Health Care
Biotech
43
iShares S&P SmallCap 600 UCITS ETF 0.22%
Equity
United States
Small Cap
1,771
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
488
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.01%
Equity
North America
Social/Environmental
27
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.05%
Equity
United States
Small Cap
180
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.